Heslop, a professor in the departments of medicine and pediatrics at Baylor, oversees the program that includes Texas Children’s Hospital and Houston Methodist Hospital.
“Dr. Heslop has been an excellent leader of this program as the interim director and it is fitting that she have this appointment,” said Dr. Paul Klotman, president, CEO and executive dean of Baylor. “Her cutting-edge research has brought the work of the Center to the forefront of cancer research and beyond that to the treatment of other diseases.”
The Center provides an infrastructure to rapidly translate novel cell and gene therapy protocols from the laboratory to the clinic. Its comprehensive approach brings a wide variety of scientists and clinicians together to develop strategies for the treatment of cancer, HIV and cardiovascular disease.
Heslop’s work focuses on translational research using adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She also serves as associate director of clinical research at the Dan L Duncan Comprehensive Cancer Center at Baylor and director of the Adult Stem Cell Transplant Program at Houston Methodist. Heslop completed her medical training at the University of Otago, New Zealand.